CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D001168: Arthritis NIH

(Synonyms: Arthri, Arthrit, Arthriti, Arthritis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (19)


Name (Synonyms) Correlation
drug267 COVID-surgRES questionaire Wiki 0.33
drug53 Adalimumab Wiki 0.33
drug1038 Placebo to match adalimumab Wiki 0.33
drug1238 Serological analyses to be lead on a pre-existing biobank Wiki 0.33
drug262 COVID-19 patients Wiki 0.33
drug260 COVID-19 infection Wiki 0.33
drug265 COVID-19 test, polymerase chain reaction for SARS-CoV-2 Wiki 0.33
drug27 40ml blood sample Wiki 0.33
drug280 Camostat Mesilate Wiki 0.33
drug1105 Questionnaire by phone call Wiki 0.33
drug256 COVID-19 convalescent hyperimmune plasma Wiki 0.33
drug272 CT-Scan Wiki 0.33
drug258 COVID-19 diagnostic test Wiki 0.33
drug910 Non-convalescent fresh frozen plasma (Standard plasma) Wiki 0.33
drug1039 Placebo to match filgotinib Wiki 0.24
drug517 Filgotinib Wiki 0.24
drug257 COVID-19 convalescent plasma Wiki 0.19
drug591 Hydroxychloroquine Wiki 0.07
drug1016 Placebo Wiki 0.05

Correlated MeSH Terms (12)


Name (Synonyms) Correlation
D001172 Arthritis, Rheumatoid NIH 0.67
D015535 Arthritis, Psoriatic NIH 0.58
D008180 Lupus Erythematosus, Systemic NIH 0.50
D001167 Arteritis NIH 0.47
D025241 Spondylarthritis NIH 0.47
D011111 Polymyalgia Rheumatica NIH 0.47
D013700 Giant Cell Arteritis NIH 0.47
D012859 Sjogren's Syndrome NIH 0.47
D001327 Autoimmune Diseases NIH 0.38
D001171 Arthritis, Juvenile NIH 0.33
D003095 Collagen Diseases NIH 0.24
D012216 Rheumatic Diseases NIH 0.19

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0001369 Arthritis HPO 0.88
HP:0001370 Rheumatoid arthritis HPO 0.58
HP:0002725 Systemic lupus erythematosus HPO 0.50
HP:0012089 Arteritis HPO 0.47
HP:0002960 Autoimmunity HPO 0.38

There are 9 clinical trials

Clinical Trials


1 A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who are naive to biologic disease-modifying anti-rheumatic drug (DMARD) therapy. The study consists of two parts, the Main Study and the Long Term Extension (LTE).

NCT04115748 Psoriatic Arthritis Drug: Filgotinib Drug: Adalimumab Drug: Placebo to match filgotinib Drug: Placebo to match adalimumab
MeSH:Arthritis Arthritis, Psoriatic
HPO:Arthritis Polyarticular arthritis

Primary Outcomes

Description: ACR20 is calculated as an at least 20% improvement from baseline in both tender and swollen joint counts and an at least 20% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, health assessment questionnaire - disability index (HAQ-DI) and an acute-phase reactant high sensitivity C-reactive protein (hsCRP).

Measure: Percentage of Participants who Achieve an American College of Rheumatology (ACR) 20% Improvement Response at Week 12

Time: Week 12

Secondary Outcomes

Description: PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS covers the physician's global assessment of disease activity and participant's global assessment of disease activity, the SF-36 PCS, swollen and tender joint counts, enthesitis and dactylitis, as well as hsCRP. A lower score indicates better function.

Measure: Change from Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)

Time: Baseline; Weeks 4, 16, 24

Description: Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), participant's assessment of pain, participant's global assessment of disease activity, HAQ-DI, and SPARCC Enthesitis Index.

Measure: Percentage of Participants who Achieved Minimal Disease Activity (MDA) Response

Time: Weeks 4, 8, 12, 16, 20, 24

Description: VLDA will be determined by tender and swollen joint counts, PASI or BSA, participant's assessment of pain, participant's global assessment of disease activity, HAQ-DI, and SPARCC Enthesitis Index.

Measure: Percentage of Participants who Achieved Very Low Disease Activity (VLDA) Response

Time: Weeks 4, 8, 12, 16, 20, 24

Description: DAPSA is a psoriatic arthritis disease activity measure, calculated by summing swollen and tender joint counts, participant's assessment of pain, participant's global assessment of disease activity, and hsCRP.

Measure: Change from Baseline in Disease Activity in Psoriatic Arthritis (DAPSA)

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: The physician's global assessment of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. The participant's psoriasis disease activity will be assessed by a physician, using a 6-point scale, which ranges from 0 (cleared) to 5 (severe).

Measure: Change from Baseline in Physician's Global Assessment of Psoriasis (PhGAP) in Participants with Psoriasis Covering ≥ 3% of the BSA at Baseline

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Measure: Change from Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) in Participants with Psoriatic Nail Involvement at Baseline

Time: Baseline; Weeks 4, 8, 12, 16, 20, 24

Description: Enthesitis will be assessed using LEI. The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).

Measure: Change from Baseline in Leeds Enthesitis Index (LEI) in Participants with Enthesitis at Baseline

Time: Baseline; Weeks 4, 8, 12, 16, 20, 24

Description: The PsAID questionnaire assesses the impact of PsA on people's lives. It is a 12-item questionnaire, where each item will be scored between 0 and 10. All items are prioritized according to importance of the health domain it represents. A higher score on the PsAID indicates more impact of the disease.

Measure: Change from Baseline in 12-item Psoriatic Arthritis Impact of Disease (PsAID-12)

Time: Baseline; Weeks 4, 16, 24

Description: PASDAS LDA is defined as PASDAS ≤ 3.2.

Measure: Percentage of Participants with Psoriatic Arthritis Disease Activity Score (PASDAS) Low Disease Activity (LDA)

Time: Baseline; Weeks 4, 16, 24

Description: PASDAS remission is defined as PASDAS ≤ 1.9.

Measure: Percentage of Participants who Achieve PASDAS Remission

Time: Baseline; Weeks 4, 16, 24

Description: ACR20 is calculated as an at least 20% improvement from baseline in both tender and swollen joint counts and an at least 20% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, HAQ-DI and an acute-phase reactant hsCRP.

Measure: Percentage of Participants who Achieve an American College of Rheumatology 20% Improvement Response

Time: Baseline; Weeks 2, 4, 8, 16, 20, 24

Description: ACR50 is calculated as an at least 50% improvement from baseline in both tender and swollen joint counts and an at least 50% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, HAQ-DI, and an acute-phase reactant hsCRP.

Measure: Percentage of Participants who Achieve an American College of Rheumatology 50% Improvement Response

Time: Weeks 2, 4, 8, 12, 16, 20, 24

Description: ACR70 is calculated as an at least 70% improvement from baseline in both tender and swollen joint counts and an at least 70% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant'ss assessment of pain, HAQ-DI and an acute-phase reactant (high sensitivity C-reactive protein [hsCRP]).

Measure: Percentage of Participants who Achieve an American College of Rheumatology 70% Improvement Response

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: Components of ACR include tender and swollen joint counts, participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, HAQ-DI and hsCRP.

Measure: Change from Baseline in Individual Components of the American College of Rheumatology Response Criteria

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: DAS28(CRP) is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), participant's global assessment of disease activity and hsCRP. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Measure: Change from Baseline in Participants who Achieve Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP)

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: DAS28(CRP) LDA is defined as DAS28(CRP) ≤ 3.2.

Measure: Percentage of Participants who Achieve DAS28(CRP) LDA

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: DAS28(CRP) remission is defined as DAS28(CRP) < 2.6.

Measure: Percentage of Participants who Achieve DAS28(CRP) Remission

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: Time to achieve DAS28(CRP) LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAS28(CRP) LDA, or censored if a participant does not achieve DAS28(CRP) LDA or missing.

Measure: Time to Achieve DAS28(CRP) LDA

Time: First dose date up to 24 weeks

Description: DAPSA LDA is defined as DAPSA ≤ 14.

Measure: Percentage of Participants who Achieve DAPSA LDA

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: DAPSA remission is defined as DAPSA ≤ 4.

Measure: Percentage of Participants who Achieve DAPSA Remission

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: Time to achieve DAPSA LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAPSA LDA, or censored if a participant does not achieve DAPSA LDA or missing.

Measure: Time to Achieve DAPSA LDA

Time: First dose date up to 24 weeks

Description: PsARC consists of four components: assessment of joint tenderness and swelling utilizing 68/66 joint counts respectively, participant's global assessment of disease activity, and physician's global assessment of disease activity.

Measure: Percentage of Participants who Achieve Psoriatic Arthritis Response Criteria (PsARC) Response

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: PASI will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent [%] to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

Measure: Change from Baseline in Psoriasis Area and Severity Index (PASI) in Participants with Psoriasis Covering ≥ 3% of the BSA at Baseline

Time: Baseline; Weeks 4, 8, 12, 16, 20, 24

Description: The PASI50 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI50 response represents at least a 50% improvement from baseline in the PASI score.

Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 50% Improvement (PASI50) Response

Time: Weeks 4, 8, 12, 16, 20, 24

Description: The PASI75 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI75 response represents at least a 75% improvement from baseline in the PASI score.

Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 75% Improvement (PASI75) Response with Psoriasis Covering ≥ 3% of the Body Surface Area

Time: Weeks 4, 8, 12, 16, 20, 24

Description: The PASI90 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI90 response represents at least a 90% improvement from baseline in the PASI score.

Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 90% Improvement (PASI90) Response

Time: Weeks 4, 8, 12, 16, 20, 24

Description: The PASI100 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI100 response represents a 100% improvement from baseline in the PASI score.

Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 100% Improvement (PASI100) Response

Time: Weeks 4, 8, 12, 16, 20, 24

Description: The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. Tenderness is quantified as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.

Measure: Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants with Enthesitis at Baseline

Time: Baseline; Weeks 4, 8, 12, 16, 20, 24

Description: LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with an at least 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [no tenderness] to 3 [tender and withdrawn]. A higher LDI indicates worse dactylitis.

Measure: Change from Baseline in Leeds Dactylitis Index (LDI) in Participants with Dactylitis at Baseline

Time: Baseline; Weeks 4, 8, 12, 16, 20, 24

Description: TDC will be assessed in participants with dactylitis at Baseline. TDC is a simple count based on the presence or absence of tender joints.

Measure: Change from Baseline in Tender Dactylitis Count (TDC)

Time: Baseline; Weeks 4, 8, 12, 16, 20, 24

Description: HAQ-DI is used to monitor the participant's self-assessed physical function or disability. This 20 -question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 function areas (getting dressed, arising, eating, walking, hygiene, reaching, gripping, and activities). HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater dysfunction.

Measure: Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)

Time: Baseline; Weeks 2, 4, 8, 12, 16, 20, 24

Description: FACIT-Fatigue is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-Fatigue total score ranges 0 to 52. Higher scores represent better fatigue status.

Measure: Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue)

Time: Baseline; Weeks 4, 16, 24

Description: The SF-36v2 is a 36-item measure that evaluates 8 domains: physical functioning, physical role functioning, general health perceptions, bodily pain, vitality, social role functioning, emotional role functioning, and mental health.

Measure: Change from Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2)

Time: Baseline; Weeks 4, 16, 24

Description: The degree of joint damage is to be assessed using the mTSS. This methodology quantifies the extent of joint erosions and joint space narrowing for 64 and 52 joints, respectively, with higher scores representing greater damage.

Measure: Change from Baseline in van der Heijde Modified Total Sharp Score (mTSS)

Time: Baseline; Week 24

2 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT04335747 Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Systemic Lupus Erythematosus Giant Cell Arteritis Other: COVID-19 infection
MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

Measure: Disease activity

Time: Last registration of disease activity in the medical journal before admission/inclusion

Secondary Outcomes

Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

Measure: Immune modulating treatments

Time: Current immune modulating treatments at admission/inclusion

Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

Measure: Biomarkers

Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1

3 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

NCT04345159 SARS-CoV-2 Systemic Lupus Erythematosus Rheumatoid Arthritis Sjogren's Syndrome Psoriatic Arthritis Other: Questionnaire by phone call
MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.

Measure: Adjusted Odds Ratio

Time: 4 months after inclusion

4 Immune Cells and the Coronavirus for Inflammatory Arthritis

A team at the University of Manchester are developing a test that tcould be helpful in detecting immunity to the Coronavirus (which causes the COVID-19 disease) in participants with inflammatory arthritis. It is based on a flu assay has already developed; the team will replace the flu antigen with a Coronavirus antigen to see if it is effective. This project aims to develop a test to see if people who have had the virus have developed immunity to it. This could help to predict who might or might not get the disease a second time, who should stay at home to be protected from potential infection or who will not develop any symptoms, even if exposed to the virus. When vaccination trials against the Coronavirus will be launched, this test could also help to see if the vaccine is effective.

NCT04363047 SARS Virus Other: 40ml blood sample
MeSH:Arthritis
HPO:Arthritis Polyarticular arthritis

Primary Outcomes

Description: the prevalence and abundance of CD4+ T lymphocytes specifically recognizing SARS-CoV-2 in COVID-19 patients with inflammatory arthritis, in pre- and post-infection samples; in patients without COVID-19 and in healthy volunteers with or without COVID-19. Correlation of these cells with COVID-19 severity.

Measure: Prevalence and abundance of CD4+ T lymphocytes

Time: 2 years

5 Antimalarial and Covid 19 in Rheumatoid Arthritis

The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

NCT04389320 Rheumatoid Arthritis Drug: Hydroxychloroquine
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: serum level

Measure: immunoglobulin mesurement

Time: 1 month

6 Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

NCT04393233 Rheumatoid Arthritis COVID
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Time: 1 Day

7 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

NCT04397237 COVID-19 Systemic Lupus Erythematosus Sjogren's Syndrome Axial Spondyloarthritis Rheumatoid Arthritis Giant Cell Arteritis
MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

Primary Outcomes

Description: ELISA tests for COVID-19 antibodies

Measure: COVID-19 seroconversion

Time: 1 day, during routine blood collection

Description: Case report form filled by the health professional

Measure: COVID-19 infection

Time: During medical visit or phone consultation, up to 2 hours

Secondary Outcomes

Description: Descriptive analysis for each disease's rate

Measure: Seroconversion rate by disease

Time: 1 day, during routine blood collection

Description: Descriptive analysis for each country's rate

Measure: Penetration across Europe

Time: 1 day, during routine blood collection

Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

Measure: COVID-19 severity

Time: During medical visit, up to 1 hour

Description: Descriptive analysis for overall and COVID-19-linked mortality rates

Measure: COVID-19 mortality rate

Time: During contact with family members, up to 1 hour

Description: Case report form filled by the health professional

Measure: COVID-19 impact on immunomodulatory treatment

Time: During medical visit, up to 1 hour

Description: Case report form filled by the patient

Measure: Patient-reported flares

Time: During medical visit, up to 1 hour

Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

Measure: Patient's fears towards COVID-19

Time: During medical visit, up to 1 hour

Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

Measure: Patient's beliefs in their medicines towards COVID-19

Time: During medical visit, up to 1 hour

8 Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients

Due to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been shown that false postive serological results often occured while detecting antibodies directed against SARS-CoV-2 in patients with positive rheumatodoid factor (RF). The investigators propose here to investigated this issue. Therefore, the investigators will test three different immunoassays on this specific population. The investigators aim to establish these assays specificity and the levels of RF for which there is a risk of anti-SARS-CoV-2 false positivity and thus ensure a better follow-up of RA patients. The RF isotype will be analysed to determine whether there is a correlation and the impact of the presence of anti-CCP (citrullinated cyclic antipeptide antibodies) will be studied and assessed.

NCT04407559 COVID-19 Rheumatoid Ar Rheumatoid Arthritis Other: Serological analyses to be lead on a pre-existing biobank
MeSH:Arthritis Arthritis, Rheumatoid
HPO:Arthritis Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Description: Evaluate the false positive results rate when using each one of the three SARS-CoV-2 serology tests in patients with rheumatoid factor plasma levels, so as to define the specificity of these tests in this RA population. all serum samples will be tested by the 3 different immunoassays. The RF plasma levels have already been measured (routine exam) and are written in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the question.

Measure: Evaluate the false positive results rate

Time: 4 months

Secondary Outcomes

Description: Characterize the RF isotype (IgG, IgM or IgA) associated with the false positivity of the test.all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions

Measure: Characterize the RF isotype (IgG, IgM or IgA) associated

Time: 4 months

Description: Determine the influence of RA on the false positivity rate in subjects with negative RF titer. All serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions

Measure: Determine the influence of RA on the false positivity rate in subjects

Time: 4 months

Description: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.

Measure: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test

Time: 4 months

Description: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.

Measure: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test

Time: 4 months

9 Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.

NCT04407923 Juvenile Idiopathic Arthritis COVID 19 Treatment
MeSH:Arthritis Arthritis, Juvenile
HPO:Arthritis Polyarticular arthritis

Primary Outcomes

Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Time: 1 Day


HPO Nodes


HP:0001369: Arthritis
Genes 263
MEFV COL2A1 NLRP3 COL1A1 COL5A1 HLA-DRB1 STAT4 MLX GPR101 IL2RA CLCN7 IL10 KLRC4 SCARB2 NOD2 MUC1 PTPN22 FGFR3 ABCG8 IL12A COPA FASLG SLC12A3 LRRC8A MATN3 COMP OCRL LACC1 IRAK1 RNASEH2B SLC37A4 ZMPSTE24 SPTB MMP13 IL12A-AS1 AGA PSTPIP1 ERAP1 SH3KBP1 TRPV4 CD79B LBR SMAD3 SPTA1 DNASE1L3 HLA-C UFSP2 TGFB3 TBX1 COL2A1 ANKH EPCAM COL2A1 NLRP3 ATP7B PTPN22 IFIH1 CLCNKB MTHFD1 HIRA SLC40A1 MVK TRPS1 GCH1 ANK1 HOXD10 UFD1 COL2A1 CD79A COL11A2 RNASEH2A HPRT1 LRBA FRZB SLC22A4 HGD BLNK PSMB9 GDF5 TCF3 KIF7 GHR HGD CCN6 FAS HLA-B LMNA ACAN CIITA JMJD1C ACAN TRAPPC2 PRG4 ADAR FCGR2A UMOD GNAS KIF22 HPRT1 AEBP1 CD244 CFI MEFV C4A COL9A2 CAV1 IL2RA UBAC2 PTPN22 FCGR2B NLRP3 RAG1 CD247 MATN3 IL23R DCLRE1C LRP6 COL9A3 LMX1B COL11A2 HLA-B SEC24C CLCN7 ADA2 BTK C1R GBA TF MMP13 ANKH PHEX COL2A1 SEC61A1 COL9A2 HLA-DRB1 SLC4A1 SLCO2A1 UFSP2 HNF1B F9 PIK3R1 GLA MMP2 COL3A1 COMP CTLA4 TLR4 COL9A3 COL1A1 ASAH1 STAT4 COL9A1 HPRT1 IL10 GJB6 CD247 COL5A2 CANT1 IL2RB BTK LEMD3 RASGRP1 CASP10 AIP ASPN COMT ACP5 FBN1 SLC26A2 MVK COMP STAT4 ARVCF WAS EPB42 NLRP12 UMOD CCN6 ZNF687 PFKM PTPN2 SLC37A4 PTPN22 TNFRSF1A HNF4A RNASEH2C TFR2 COL5A1 TREX1 COMP PSMB4 DNASE1 DNAJB11 EXT1 NOD2 BTK APOE NLRC4 TRPV4 TBX1 PRKCD COL2A1 F8 TREX1 COL2A1 MYH14 PRPS1 SMAD3 IL36RN HPGD ANKRD55 C1QA SAMHD1 COL11A2 MATN3 EXT2 PHEX RREB1 CCR6 RAG2 ANKRD55 CCN2 HJV MEFV IL12B IRF5 FAS CCR1 COL11A1 STAT4 NFKBIL1 PSTPIP1 COL9A1 TRAPPC2 ACAN G6PC HLA-DRB1 COL2A1 SPP1 IL2RB MMP14 HPGD PADI4 GP1BB RNF168 PTPN22 COL2A1 WIPF1 NLRP3 HPRT1 PTPN2 IGHM FAS GJB2 HPGD STAT3 IGLL1 MEFV IL6 ATP7B HNF1B HLA-B MIF
Protein Mutations 4
A147T N363S R620W V600E